An important element of FibroGen's financial strategy is to assure adequate funding of Company operations and to maintain 3-5 years of cash compared to burn rate. Since its inception, FibroGen has been able to raise sufficient capital to maintain a margin of safety against its core burn rate. A variety of sources of financing have been used to accomplish this including private equity and financing grants related to FibroGen's subsidiary FibroGen Europe Corp.

Selected major investors in FibroGen have included:

Adage Capital Management
Apothecary Capital
American Express
Astellas Pharma, Inc.
Brookside Capital Partners (an affiliate of Bain Capital)
BankInvest Biomedical Development
Bio Fund Ventures II OY / Mgmt Oy
Blue Anchor Holdings Corp.
Corriente Biotechnology Partners
Credit Suisse London Nominees
Duquesne Capital Management
Franklin Fairview
Franklin Templeton
Goldman Sachs
Janus Capital Group
Maverick
Merlin BioMed Group
Och-Ziff Capital Management
The Parthenon Group
Pictet Bank
Privat Kredit Bank
The Rosewood Corporation
Sedgefield Investments
Sigma Capital Management
SITRA
SMBC Capital (the private equity arm of Sumitomo Mitsui Banking Corporation)
Taisho Pharmaceutical Co., Ltd.
Three Arch Bay Health Science Fund I, L.P.
TPG Axon
T. Rowe Price
Wagner & Brown